Search Results for “EC” – Page 166 – media

GlaxoSmithKline wins first-ever nod for blockbuster vaccine prospect Shingrix

Just as GlaxoSmithKline nears a decision from the U.S. FDA for its key shingles vaccine, Shingrix, Canada has become the first country to approve the shot—and it's a key piece of CEO Emma Walmsley's prescription for growth at the drugmaker.
- Source: fiercepharma
- 601
- October 19, 2017
New Approvals shingles vaccine
AstraZeneca admits cancer data for acquired drug was fabricated

AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified.
- Source: Pharmafile
- 633
- October 19, 2017
acalabrutinib AstraZeneca blood cancer solid tumour
Neurotech International bags $4M to commercialise autism device

Neurotech International Ltd has successfully raised $4 million via a placement of shares at $0.20 each to drive its ongoing commercialisation of the Mente Autism device.
- Source: proactiveinvestors
- 665
- October 18, 2017
ASD autism Company Insight EEG medical device
A Significant Global Problem

A study of the global prevalence of fetal alcohol spectrum disorder (FASD) estimates that it affects as many as 8 out of 10,000 children, highlighting the need to improve public education about the potential harm of drinking alcohol during pregnancy.
- Source: medicalnewsbulletin
- 514
- October 18, 2017
alcohol FASD fetus Market Views
AstraZeneca’s Imfinzi gets speedy US review for lung cancer

US regulators have accepted an application by AstraZeneca and MedImmune to expand the scope of Imfinzi (durvalumab) to include patients with a certain form of lung cancer.
- Source: Pharmatimes
- 784
- October 18, 2017
AstraZeneca FDA Imfinzi (durvalumab) lung cancer
NICE flip-flops to back Bristol’s Opdivo in head and neck cancer despite data ‘uncertainties’

Back in April, England’s cost watchdogs said they wouldn’t cover Bristol-Myers Squibb’s Opdivo in head and neck cancer due to “uncertain” clinical evidence. Now, though, they’re singing a different tune.
- Source: Fiercepharm
- 547
- October 16, 2017
New Approvals NHS Opdivo
Ardelyx’s Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

Ardelyx, Inc. (ARDX) reported positive results from T3MPO-2, its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation (IBS-C). The study hit statistical significance for the primary endpoint and all secondary endpoints evaluated for the topline results and demonstrated the ability to normalize bowel movements.
- Source: finance.yahoo
- 553
- October 16, 2017
bowel syndrome Clinical Trials constipation
How to quote – the key to receiving orders

Creating quotations is a commercial practice used to reply to clients’ inquiries. There is however far more to a quotation than simply giving price estimates. In fact, it directly relates to the client’s first impression of you and your company.
- Source: Ddu
- 622
- October 13, 2017
Ddu College quotations
Roche secures FDA approval for Zika virus screening test

Roche has secured approval from the US Food and Drug Administration (FDA) for its cobas Zika test to detect RNA of the Zika virus in human plasma samples.
- Source: medicaldevice-network
- 675
- October 11, 2017
FDA New Approvals plasma Zika
Magenta Medical, Developer of Novel Heart Failure Therapies, Secures $15 Million in Series B Financing

Magenta Medical was founded in October, 2012 by Prof. Ehud Schwammenthal and Mr. Yosi Tuval, Magenta Medical is developing novel therapeutic approaches to the management and treatment of Acute Heart Failure.
- Source: Infomeddnews
- 439
- October 11, 2017
Acute Heart Failure Market Views therapeutic

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.